Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
Top HIV expert is not donating to crowdfunding HIV vaccine campaign, says it's "Fake News"

Dr. Carl W. Dieffenbach, head of the AIDS division of the US National Institutes of Health, has denounced an HIV vaccine crowdfunding campaign involving prominent stars. The major fundraising #ENDHIV campaign which features SIA, the campaign’s ambassador. Other celebrities include Zoe Saldana and Julianne Moore. Dr Dieffenbach's assessment is not pointed at the celebrities nor the organisation behind the campaign. It’s about the research of scientist, Dr. Paul, whom Dieffenbach asserts “is wrong” in his direction towards discovering the vaccine or cure promoted by the video and the campaign’s website www.endhiv.com. Yet, the #ENDHIV video calls Dr. Paul’s work “a promising new AIDS cure.”

Published
17 June 2017
From
imstilljosh
HIV drug resistance testing not a priority for resource-limited settings, trial finds

Resistance testing is unlikely to improve the effectiveness of second-line HIV treatment in resource-limited settings and the introduction of routine HIV drug resistance testing is

Published
14 June 2017
By
Keith Alcorn
SA's new HIV challenge: patients who believe they've been healed

On the eve of South Africa’s national AIDS conference taking place in Durban this week, it has emerged that people are defaulting on their ARVs – often under the impression that they have been healed. According to health workers Health-e News spoke to, the issue relates to the “undetectable viral load” diagnosis patients receive when their antiretroviral therapy starts working and causes the amount of virus in their blood to drop to an extremely low level.

Published
13 June 2017
From
Citizen
Study: 1 in 3 Patients Starts HIV Treatment Late in 10 Countries

A large team of international researchers has found 30 percent of HIV positive individuals in nearly a dozen countries delay starting life-saving drugs. A study spearheaded by the U.S. Centers for Disease Control and Prevention looked at the prevalence of HIV in Haiti, Vietnam, Nigeria, Namibia, Swaziland, Zimbabwe, Mozambique, Tanzania, Uganda and Zambia.

Published
09 June 2017
From
Voice of America
Meds May Impact Prenatal Screening in HIV+ Patients

Pregnant women with HIV taking integrase inhibitors at the time of their non-invasive prenatal screening test had a lower mean fetal fraction than those who were not taking the medication, a small study found here.

Published
08 June 2017
From
MedPage Today HIV/AIDS
Experts raise concerns over high HIV treatment failure in Kenya

Local and international health authorities are concerned about emerging evidence of high HIV treatment failure in Kenya. The latest findings in a report by the Ministry of Health and the UN published last week spoke of "unacceptably" high failure rates of Anti-retrovirals (ARVs) among refugees and residents of Kakuma in northern Kenya.

Published
06 June 2017
From
The Standard
ViiV Healthcare Files Regulatory Submissions for First Two-Drug HIV Maintenance Regimen

GSK and ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced regulatory submissions to the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) for a single-tablet, two-drug regimen of dolutegravir (Tivicay, ViiV Healthcare) and rilpivirine (Edurant, Janssen Sciences Ireland UC) for the maintenance treatment of HIV-1 infection.

Published
02 June 2017
From
ViiV
HIV: A therapeutic advance for resource-limited settings

ANRS 12286 MOBIDIP, a clinical trial running in parallel in three countries in sub-Saharan Africa, shows that dual therapy with lamivudine and a boosted protease inhibitor is effective as second-line treatment in patients infected by HIV with multiple mutations. Such treatment deescalation will reduce costs, side effects, and the need for virological monitoring of patients. The results of this study are published in The Lancet HIV.

Published
31 May 2017
From
Eurekalert Inf Dis
Gilead and GSK go head-to-head with similar HIV drug data

Gilead Sciences Inc and GlaxoSmithKline Plc will go head-to-head with rival versions of an improved class of HIV medicines, after clinical studies showed the U.S. company's new drug bictegravir was as effective as GSK's product.

Published
31 May 2017
From
Reuters
Gilead’s Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for the Treatment of HIV-1 Meets Primary Endpoint in Four Phase 3 Studies

Gilead Sciences, Inc. (Nasdaq:GILD) today announced that four Phase 3 studies evaluating a fixed-dose combination of bictegravir (50mg) (BIC), a novel investigational integrase strand transfer inhibitor (INSTI), and emtricitabine/tenofovir alafenamide (200/25mg) (FTC/TAF) for the treatment of HIV-1 infection met their primary objectives of non-inferiority.

Published
30 May 2017
From
Gilead press release

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.